Qureight Raises $20 Million For AI Chest Imaging Lab
Qureight announced a $20 million Series B led by Molten Ventures to build an AI imaging laboratory around its 3D chest Foundation Model for lung and heart clinical trials.

Qureight has raised $20 million to turn its chest-imaging models into a reusable AI platform for lung and heart clinical trials.
The Cambridge company said Molten Ventures led the Series B round on July 29, 2026, with Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind and Ascension participating.
The money will fund an AI imaging laboratory built around Qureight’s 3D chest foundation model.
Series B Backs A 3D Chest Imaging Foundation Model
The product plan focuses on quantitative imaging rather than a standalone diagnostic app.
The platform encompasses global imaging CRO services for image handling, rapid site onboarding, and patient-inclusion decisions; AI Lung image biomarkers that quantify compartment-specific structural changes during disease progression; and data science products, including synthetic control arms for comparisons against real trial arms.
These components support trial design and endpoint measurement.
Drug developers engaged in imaging-heavy lung and heart studies require repeatable image handling, measurable disease markers, and trial-arm comparisons before a model can influence protocol design.
The laboratory is positioned as a means to adapt one foundation model across disease-specific products, rather than creating a separate model from scratch for each target condition.
Lung And Heart Trial Market Forecast Reaches $27.5bn
Qureight estimates that the global lung and heart clinical-trials market could reach USD $27.5bn by 2030, with a CAGR of 6.9% over the next six years.
The Series B is framed as support for commercial expansion across new therapeutic markets and further development of the AI-powered quantitative imaging analytics platform.
The company also added two board appointments tied to the round.
Dr Inga Deakin, a partner at Molten Ventures, joined the board, while Anna Salim of Hargreave Hale also took a board seat.
Existing investors stayed in the financing, keeping the round within the investor group named in the release.
Clinical-Trial Claims Still Depend On Partner Proof
The release outlines product scope, funding size, investor names, and target disease areas, but the strongest performance language remains company-owned.
Molten Ventures connected the platform to AI systems trained on real-world data for clinical research, while Qureight presented its platform as a source of real-time insights and precision endpoints for biopharma partners.
Trial-level time savings and regulatory outcomes are not quantified in the Series B release.




















